Alvocidib

CDK9 inhibitor studied for leukemia and inflammatory diseases

Alvocidib (INN; also known as Flavopiridol) is a synthetic flavonoid alkaloid and a potent inhibitor of cyclin-dependent kinase 9 (CDK9), currently under clinical development for the treatment of acute myeloid leukemia (AML). It is being developed by Tolero Pharmaceuticals, Inc.

Mechanism of Action

Alvocidib exerts its effect primarily through inhibition of the positive transcription elongation factor b (P-TEFb), which is essential for transcription elongation by RNA polymerase II. Inhibition of P-TEFb by alvocidib leads to suppression of mRNA synthesis, resulting in the downregulation of genes critical for cell survival and proliferation, particularly in rapidly dividing cells such as leukemic blasts.

Clinical Applications

Alvocidib is primarily being investigated for its potential role in:

• Acute myeloid leukemia (AML) – ongoing clinical trials are evaluating its efficacy and safety in relapsed or refractory AML patients.

Other studied indications include:

• Rheumatoid arthritis – due to its anti-inflammatory properties
• Atherosclerosis – for its potential to modulate inflammatory pathways and reduce plaque formation

Research and Development

Alvocidib has shown promising preclinical and early-phase clinical trial results. It is often studied in combination with other agents such as:

• Cytarabine
• Mitoxantrone
• Bcl-2 inhibitors (e.g., venetoclax)

These combinations aim to enhance apoptosis and overcome resistance mechanisms in AML.

See Also

• CDK inhibitors
• Transcription regulation
• Acute myeloid leukemia
• Small molecule therapeutics